L3VLUP
ProSign in

CABA · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CABAARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CABA
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterCABAARGX
Q3 2020none listed holders, n.a.8 holders, $3.6bn
Q4 2020none listed holders, n.a.7 holders, $4.1bn
Q1 2021none listed holders, n.a.8 holders, $4.1bn
Q2 2021none listed holders, n.a.9 holders, $4.6bn
Q3 20211 holders, $11m8 holders, $4.5bn
Q4 2021none listed holders, n.a.9 holders, $5.3bn
Q1 2022none listed holders, n.a.8 holders, $5.3bn
Q2 2022none listed holders, n.a.13 holders, $6.5bn
Q3 2022none listed holders, n.a.14 holders, $5.3bn
Q4 2022none listed holders, n.a.13 holders, $5.5bn
Q1 2023none listed holders, n.a.13 holders, $5.9bn
Q2 20231 holders, $2.3m18 holders, $6.6bn
Q3 20233 holders, $23m21 holders, $8.7bn
Q4 20234 holders, $57m17 holders, $6.3bn
Q1 20242 holders, $9.9m13 holders, $6.8bn
Q2 20242 holders, $4.3m14 holders, $7.9bn
Q3 2024none listed holders, n.a.13 holders, $10.7bn
Q4 2024none listed holders, n.a.14 holders, $12.3bn
Q1 2025none listed holders, n.a.17 holders, $11.8bn
Q2 2025none listed holders, n.a.18 holders, $10.8bn
Q3 2025none listed holders, n.a.16 holders, $13.8bn
Q4 2025none listed holders, n.a.16 holders, $14.8bn
Q1 2026none listed holders, n.a.11 holders, $12.3bn
Q2 20261 holders, $13m14 holders, $15.0bn
CABA

Cabaletta Bio Inc

Holders
4
Reported value
$57m
Buyers
3
Sellers
1

Breadth +2 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
17
Reported value
$6.3bn
Buyers
12
Sellers
6

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2023

Among the 19 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CABA (2)

Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC

Only ARGX (15)

Artisan Partners LP, Balyasny Asset Management LLC, Capital World Investors, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, Point72 Asset Management LP, T. Rowe Price Associates Inc, Verition Fund Management LLC, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →